Association of Pentraxin3 with Severity of Heart Failure Due to Different Etiologies
/ 0
- Details
- Category: Vol. 78, June 2010
- Hits: 990
Association of Pentraxin3 with Severity of Heart Failure Due to Different Etiologies,BAHAA D.M. GRACE, YASSER M. ABDELHAMID, MANAL A. AZIZ and REEM J. FAREED
Abstract
Background: Pentraxin3 (PTX3) is an acute phase protein that is expressed locally in response to a variety of infectious and inflammatory responses. Although both short and long pentraxins are acute phase proteins involved in the innate immunity and inflammation, yet a long pentraxin, (PTX3), is produced by vascular cells or inflammatory cells and released into the circulation, possibly reflecting local inflammation in the cardiovascular system. Plasma PTX3 levels might be a potentially useful biomarker to predict prognosis as well as to detect inflammatory status in patients with congestive heart failure (CHF).
Objective: The aim of this work is to evaluate the useful-ness of Pentraxin3 in the stratification of morbidity in heart failure patients including etiology, severity and risk factors of heart failure.
Methodology: This study included 50 subjects divided into: 30 patients (Group A) were diagnosed as having features of heart failure based on:
1-Echo cardiographic finding (ejection fraction less than 50%).
2-NYHA classification.
In addition to 20 normal controls (group B). All patients were subjected to clinical evaluation, laboratory investigations, echocardiography and measurment of plasma pentraxin3 level.
Results: Pentraxin3 levels were positively correlated with patients classification by NYHA and negatively correlated with the percentage of ejection fraction. Moreover, Pentraxin3 level was significantly higher in patients with moderate and severe degree of heart failure (NYHA III and IV) than those with mild disease (NYHA I and II).
Conclusion: Plasma Pentraxin3 is a useful marker for detection of severity of heart failure independent of age, sex and C-reactive protein (CRP).
Plasma Pentraxin3 level in heart failure does not differ between patients with or without hypertension, diabetes mellitus, hyperlipidemia, ischemic heart disease, rheumatic heart disease or cardiomyopathy as risk factors or etiological factors for heart failure.